Hansoh Biotech Presents Novel Bispecific Antibody and ADC Research at AACR 2026
核心洞察
Hansoh Biotech (搜索) presented four core preclinical research results at the 2026 AACR Annual Meeting in San Diego from April 17-22.
The company showcased studies on novel CTLA4xCD47 bispecific antibody HX044 and multi-mechanism PD-L1xVEGF antibody-drug conjugate HX116 (搜索) for solid tumor treatment.
Research demonstrated that 3D tumor organoids provide superior prediction of antibody-drug conjugate anti-tumor efficacy compared to 2D cell models.
Hansoh Biotech (搜索)-B presented four core preclinical research results at the 2026 American Association for Cancer Research (AACR) Annual Meeting held in San Diego from April 17 to 22, showcasing the company's advancing pipeline of novel cancer therapeutics.
Novel Bispecific Antibody Research
The company presented a preclinical pharmacokinetic and pharmacodynamic model study of its novel CTLA4xCD47 bispecific antibody HX044, which included a comparative evaluation of its therapeutic window versus ipilimumab. This research represents Hansoh's efforts to develop next-generation immunotherapies that target multiple pathways simultaneously.
Multi-Mechanism Antibody-Drug Conjugates
Hansoh showcased research on its novel multi-mechanism PD-L1xVEGF antibody-drug conjugate HX116 (搜索) for the treatment of solid tumors (搜索), examining potential synergistic effects. The company also presented findings on a novel multi-mechanism PD-L1 (搜索) antibody-drug conjugate with enhanced tumor specificity, positioning it as a potential pan-solid tumor therapeutic candidate.
Improved Preclinical Modeling
The research portfolio included findings demonstrating that 3D tumor organoids are superior to 2D cells in more accurately predicting the in vivo anti-tumor efficacy of antibody-drug conjugates. This methodological advancement could improve the translation of preclinical research to clinical outcomes.
The presentations at AACR 2026 highlight Hansoh Biotech (搜索)'s focus on developing innovative cancer therapeutics, including bispecific antibodies and antibody-drug conjugates that target multiple mechanisms of action for enhanced therapeutic potential in solid tumor treatment.